Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Presumed Ocular Histoplasmosis Syndrome
NCT07695298Phase 4Recruiting
- Sponsor
- Cincinnati Eye Institute
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in Ocular Histoplasmosis Syndrome (OHS), sponsored by Cincinnati Eye Institute. Primary endpoint: Central Macular Subfield Thickness at 52 weeks. Started Jul 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
Ocular Histoplasmosis Syndrome (OHS)
Beyond the preview
Go deeper on NCT07695298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695298.